Delcath Systems reports $20.7mln Q4, $85.2mln FY25 revenue.

lunes, 12 de enero de 2026, 4:44 pm ET1 min de lectura
DCTH--

• Delcath Systems reports preliminary Q4 and FY25 financial results • Total Q4 revenue expected at $20.7 million, FY25 at $85.2 million • HEPZATO KIT Q4 revenue expected at $19 million, FY25 at $78.8 million • CHEMOSAT Q4 revenue expected at $1.7 million, FY25 at $6.4 million • Focus on primary and metastatic cancers of the liver treatment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios